Market: NMS |
Currency:
Address:
📈 ONC Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$410.21
-
Upside/Downside from Analyst Target:
20.89%
-
Broker Call:
47
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
50-100%
-
Revenue Growth Range (1Y):
25-50%
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for ONC
| Date | Reported EPS |
|---|
| 2025-11-10 | - |
| 2025-08-06 | 0.84 |
| 2025-05-07 | 0.01 |
| 2025-02-27 | -1.43 |
| 2024-11-12 | -1.15 |
| 2024-08-07 | -1.15 |
| 2024-05-08 | -2.41 |
| 2024-02-26 | -3.48 |
| 2023-11-09 | 2.01 |
| 2023-08-02 | -3.64 |
| 2023-05-04 | -3.34 |
| 2023-02-27 | -4.29 |
| 2022-11-09 | -5.39 |
| 2022-08-04 | -5.56 |
| 2022-05-05 | -4.24 |
| 2022-02-25 | -6.16 |
| 2021-11-04 | -4.46 |
| 2021-08-05 | -5.23 |
| 2021-05-06 | 0.69 |
| 2021-02-25 | -5.2 |
| 2020-11-05 | -4.81 |
| 2020-08-06 | -4.31 |
| 2020-05-11 | -4.7 |
| 2020-03-02 | -6.39 |
| 2019-11-12 | -5.11 |
📰 Related News & Research
-
Concentrix Corp 2026 Q1 Earnings Report: Financial Results, Revenue, and Key Highlights
April 4, 2026
Concentrix Corporation Q1 2026 Financial Report: Key Highlig...
-
Future Money Acquisition Corp 2026 Financial Statements: IPO Proceeds, Trust Account, and Going Concern Risks Explained
April 4, 2026
Future Money Acquisition Corporation Releases Audited Financ...
-
NeOnc Technologies Reports Q4 2025 Results, Advances NEO100 & NEO212 Clinical Trials, and Secures $10M PIPE Financing
April 4, 2026
NeOnc Technologies Holdings, Inc. Q4 2025 Investor-Focused U...
-
Sunshine Biopharma Inc. 2025 Annual Report: Generic Drug Portfolio, Proprietary Oncology & Antiviral Developments, and Corporate Strategy
April 4, 2026
Sunshine Biopharma Inc. 2025 Annual Report - Investor Analys...
-
GRP Limited Announces Full Settlement and Conclusion of Dispute with EESB 1
April 3, 2026
GRP Limited: Resolution of Legal Dispute with EESB GRP Lim...
-
Perspective Therapeutics Advances First-in-Class 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment
April 2, 2026
Perspective Therapeutics Unveils Promising Clinical Data and...
-
I.T.S. Industrial Techno-Logic Solutions Ltd. 2024 Audited Financial Statements Reveal Significant Losses and Going Concern Risks
April 1, 2026
I.T.S. Industrial Techno-Logic Solutions Ltd. Releases 2024 ...
-
Concrete Pumping Holdings Acquires Templant Hire Limited to Enter UK Temporary Power Market
April 1, 2026
Concrete Pumping Holdings Announces Strategic Acquisition of...
-
Oncolytics Biotech Completes Move to U.S., Becomes Nevada Corporation and Sets San Diego as New Headquarters
April 1, 2026
Oncolytics Biotech Completes U.S. Domicile Change - Key Inve...
-
Geo Energy Acquires Majority Stake in Coking Coal Concession, Expanding into High-Value Steelmaking Market
April 1, 2026
Geo Energy’s Strategic Entry into Coking Coal: Transformatio...
🔍 View more Reports
